Avapritinib

The FDA announced several regulatory actions the past few weeks.

Wastage from dose reduction or discontinuation of the most common oral anticancer drugs costs a mean of $4,290 per patient, results of a retrospective study showed.

The FDA approved avapritinib for treatment of adults with indolent systemic mastocytosis, according to a press release from the agent’s manufacturer.

The FDA approved avapritinib for treatment of adults with advanced systemic mastocytosis.

The FDA granted breakthrough therapy designation to avapritinib for treatment of moderate to severe indolent systemic mastocytosis, according to the agent’s manufacturer.